Parabilis Medicines Prices Upsized IPO at $20 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: NASDAQ.COM
- IPO Size Announcement: Parabilis Medicines has announced the pricing of its upsized initial public offering (IPO) of 33.5 million shares at $20 per share, with expected gross proceeds of $670 million, reflecting strong market confidence in its biopharmaceutical prospects.
- Concurrent Private Placement: In addition, Parabilis has agreed to sell 4.167 million shares of common stock at $18 per share to Regeneron Pharmaceuticals, which is expected to generate approximately $75 million in additional funding, further strengthening its capital base.
- Trading Timeline: Parabilis shares are expected to begin trading on Nasdaq on June 10, 2026, under the ticker symbol “PBLS,” with the offering anticipated to close around June 11, 2026, ensuring timely access to funds to support its R&D activities.
- Underwriter Support: The offering is being managed by Leerink Partners, BofA Securities, Evercore ISI, and Guggenheim Securities, indicating strong market endorsement of Parabilis's innovative Helicons therapeutic modality, which may drive further advancements in the biopharmaceutical sector.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
